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Gene regulationHIF-1α is degraded by oxygen-dependentmechanisms but stabilized in hypoxia to form transcriptional complex
HIF-1, which transactivates genes promoting cancer hallmarks. However, howHIF-1α is speciﬁcally regulated in
hypoxia is poorly understood. Here, we report that the histonemethyltransferase SET9 promotes HIF-1α protein
stability in hypoxia and enhances HIF-1 mediated glycolytic gene transcription, thereby playing an important
role in mediating cancer cell adaptation and survival to hypoxic stress. Speciﬁcally, SET9 interacts with HIF-1α
and promotes HIF-1α protein stability in hypoxia. Silencing SET9 by siRNA reduces HIF-1α protein stability
in hypoxia, and attenuates the hypoxic induction of HIF-1 target genes mediating hypoxic glycolysis. Mechanis-
tically, we ﬁnd that SET9 is enriched at the hypoxia response elements (HRE) within promoters of the HIF-1-
responsive glycolytic genes. Silencing SET9 reduces HIF-1α levels at these HREs in hypoxia, thereby attenuating
HIF-1-mediated gene transcription. Further, silencing SET9 by siRNA reduces hypoxia-induced glycolysis and
inhibits cell viability of hypoxic cancer cells. Our ﬁndings suggest that SET9 enriches at HRE sites of HIF-1 respon-
sive glycolytic genes and stabilizes HIF-1α at these sites in hypoxia, thus establishes an epigenetic mechanism of
the metabolic adaptation in hypoxic cancer cells.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The transcription factor hypoxia-inducible factor 1 (HIF-1) plays an
essential role in cellular adaptation to hypoxic stress [1]. HIF-1 consists
of an oxygen-sensitive α subunit (HIF-1α) and a constitutive β subunit
(HIF-1β) [2,3]. The activity of HIF-1 is implicated in cancer development
and therapy resistance [4]. This is because HIF-1 controls gene expres-
sion programs for cancer hallmarks, including metabolic adaptation,
angiogenesis, metastasis and stem cell maintenance [5]. An increase of
glucose metabolism represents a major event in metabolic adaptation
to hypoxic stress [6]. Notably, HIF-1 controls genes increasing glycolysis,
which cancer cells often employ to gain growth advantage over normal
cells [7–9]. The activity of HIF-1 primarily depends on HIF-1α, which is
stabilized by tumor hypoxia and oncogenic mutations [3]. In many
human cancers, the expression level of HIF-1α is associated with poor
prognosis and mortality [6]. Thus, HIF-1α is widely considered as an
important therapeutic target to treat cancer [10].poxia response element; PHD,
cell lysate; HK2, hexokinase 2;
enase kinase, isozyme 1; ENO1,
; JMJD2C, jumonji domain con-
acting protein
University, 3303 SW Bond Ave,In normoxia, the HIF-1α subunit is constantly synthesized, but rap-
idly degraded by the oxygen-dependent mechanism, mainly through
the prolyl hydroxylase (PHD) and the von Hippel–Lindau (VHL) me-
diated ubiquitin proteasomal degradation [11,12]. Several oxygen-
independent mechanisms were also reported to regulate HIF-1α
stability, suggesting HIF-1α stability is also regulated in hypoxia. For
example, RACK1 competes with the chaperon HSP90 and promotes
HIF-1α degradation [13,14], HSP70 and the ubiquitin E3 ligase CHIP
promote ubiquitin proteasomal degradation of HIF-1α [15].
Transcription of genomic sequences is dependent on the accessibility
of chromatin to transcriptionmachinery including transcriptional factors
and cofactors [16]. As transcriptional cofactors, several histonemodifying
enzymes have been reported to regulate HIF-1 transactivation. The
histone acetyltransferase p300 and histone deacytylases (HDACs) regu-
late HIF-1 transcriptional activity by acetylation/deacetylation [17–22].
The histone methyltransferase G9a and histone demethylase jumonji
domain containing protein 1A (JMJD1A) and JMJD2C regulate HIF-1
transactivation through methylation/demethylation of histone and
non-histone proteins [23–25]. However, howHIF-1 transcriptional activ-
ity and target gene expression were selectively regulated by histone
modifying enzymes is unclear.
Genome wide study indicated that HIF-1 preferentially binds to
transcriptional active loci, which already presented under normal con-
dition, as characterized by H3K4 methylation [26,27]. SET9 is a lysine
mono-methyltransferase for histone H3K4 and is thus involved in
gene activation through inhibiting heterochromatin formation [28–30].
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expressions in hypoxia.
Here we report that the histone methyltransferase SET9 enriches at
HRE sites within glycolytic HIF-1 target gene promoters and stabilizes
HIF-1α protein at these sites by inhibiting proteasomal degradation in
hypoxia. Therefore SET9 facilitates HIF-1 to upregulate glycolytic
genes and promotes the glycolytic adaptation of cancer cells to hypoxic
stress. Our study demonstrates that SET9 is a potential molecular target
to inhibit HIF-1α and HIF-1 mediated cancer development.
2. Materials and methods
2.1. Cell lines and reagents
Hep3Bc1, a gift fromDr. Gregg Semenza at Johns HopkinsUniversity,
was stably transfected with HRE driven ﬁreﬂy luciferase reporter (p2.1)
and constitutive renilla luciferase reporter (pSV-renilla) [31]. Human
embryonic kidney 293T (HEK293T), osteosarcoma U2OS, hepatoma
Hep3Bc1, and renal cell carcinoma RCC10 cells were cultured in
DMEM with 10% FBS as described previously [32]. Human prostate
cancer cell lines DU145 and C42B were cultured in RPMI medium as
described [33]. The hypoxic condition was deﬁned as 1% oxygen, 5%
CO2 and 94% nitrogen. MG132 was purchased from Cayman Chemical
(Ann Arbor, MI).
2.2. Plasmids and transfection
Plasmids encoding 3×FLAG-HIF-1α, p2.1, and pSV-renilla were gifts
from Dr. Gregg Semenza at Johns Hopkins University. Plasmids
encoding HA-HIF-1α, HA-HIF-2α, CHIP, FLAG-SET9 and FLAG-SET9-
H297A were from Addgene (Cambridge, MA). Plasmid encoding HA-
SET9 was purchased from Sino Biological (Beijing, China). Plasmid
transfection was performed using X-tremeGENE 9 transfection reagent
from Roche (Indianapolis, IN) following the manufacturer's instruc-
tions. Scramble control (siC) and SET9 siRNA (siSET9) constructs were
purchased from Sigma (St. Louis, MO). Transient siRNA knockdown
was performed using Dharmafect reagents from Thermo Scientiﬁc
(Pittsburgh, PA) following the manufacturer's instructions.
2.3. Stable cell lines
The pLKO.1-puro vector based lentiviruses containing HIF-1α, SET9
or non-targeting control shRNA were purchased from Sigma. Establish-
ment of shC, shHIF-1α and shSET9 stable knockdown cell lines was
described previously [32,34]. Stable cell lines were selected and main-
tained in growth medium supplemented with puromycin.
2.4. Immunoprecipitation (IP) and western blotting
Cells were harvested using lysis buffer (50 mM Tris–HCl, 150 mM
NaCl, 0.1% NP-40, pH 7.4) and debris were removed by centrifugation
at 12,000 rpm for 10 min. For HIF-1α IP, cell lysates were incubated
with anti-HIF-1α antibody overnight at 4 °C, and then incubated with
protein A/G agarose (Santa Cruz Biotechnology, Dallas, TX) for 4 h. The
agarose was precipitated and washed with PBS for 3 times, and protein
was recovered with 1× Laemmli sample buffer (Bio-Rad, Hercules, CA)
at 95 °C for 10 min. For FLAG IP, cell lysates were incubated with anti-
FLAGM2afﬁnity gel (Sigma) for 4 h at 4 °C, and then the gelwaswashed
with PBS for 3 times and the protein was recovered as above. For west-
ern blotting, equal amounts of cell lysates (40–60 μg of protein)were re-
solved with SDS-PAGE, and transferred to membranes. The membrane
was probed with primary antibodies, washed, and then incubated
with corresponding ﬂuorescent secondary antibodies and washed. The
ﬂuorescent signal was captured using LI-COR (Lincoln, NE) Odyssey Im-
aging System, and ﬂuorescent intensity was quantiﬁed using the Odys-
sey software where indicated. Antibodies used were: HIF-1α (SantaCruz), HIF-2α (Novus Biologicals, Littleton, CO), SET9 (Millipore, Biller-
ica, MA), β-tubulin (Sigma), FLAG-M2 (Sigma), HA (Abcam, Cambridge,
MA), and CHIP (Santa Cruz).
2.5. Quantitative RT-PCR
U2OS cells were transfected with scramble control (siC) or SET9
siRNA (siSET9) for 48 h, during which cells were exposed to 20% or 1%
O2 for 24 h prior to harvest. Real-time PCRwas performed as previously
described [35]. Brieﬂy, total RNA was extracted using TRIzol reagent,
reverse transcribed to cDNA, and quantiﬁed by real-time PCR using
sybrgreen universal master mix (all reagents were from Life Technolo-
gies, Grand Island, NY). 18S rRNA was used as internal reference and
siC cells in 20% O2 were used as control. Results were calculated using
the ΔΔCt method. ΔCt = Ct − Ct (18S rRNA), ΔΔCt = ΔCt − ΔCt
(control), fold change to control = 2^(−ΔΔCt). RT-PCR primer pairs
for HIF-1α target genes were described previously [32].
2.6. Reporter gene assays
Hep3Bc1 cells stably expressing p2.1 and pSV-renilla [31] were cul-
tured in 24-well plates and transfectedwith siC or siSET9 siRNA for 48h.
HEK293T cells were transfectedwith p2.1, pSV-renilla, and siC or siSET9
siRNA for 48 h. Luciferase activity was measured using dual-luciferase
assay system (Promega, Madison, WI). Fireﬂy luciferase activity was
normalized by renilla signals, and expressed as relative HRE activity
compared to control cells (siC in 20% O2).
2.7. Chromatin immunoprecipitation assay
U2OS cells were exposed to 20% or 1% O2 for 24 h and ﬁxed by 1%
formaldehyde. ChIP assay was performed using ChIP-IT express kit
from Active Motif (Carlsbad, CA) according to the manufacturer's
protocol. The recovered DNA was quantiﬁed using Real-time PCR.
Primer pairs amplifying the HRE regions of HIF-1α target genes were
designed as described [27]. The enrichment fold was calculated based
on ΔCt = Ct − Ct (input), ΔΔCt = ΔCt − ΔCt (IgG), fold change =
2^(−ΔΔCt).
2.8. Lactate assay
U2OS cells were cultured in 24-well plates for 24 h, and then
transfected with scramble control siRNA or SET9 siRNA for 24 h. Cells
were switched to fresh growth medium and exposed to 20% or 1% O2
for an additional 24 h. Cell culture medium was used for lactate mea-
surement with a lactate assay kit II (Sigma) following the
manufacturer's instructions. Lactate content was normalized by cell
number and expressed as fold change over control (siC cells in 20% O2).
2.9. Cell viability assay
Cell viability was measured as previously described [33]. U2OS shC
and shSET9 cells were seeded in 96-well plates and cultured for 24 h,
whichwas deﬁned as day 0 in hypoxia (1% O2). Cells were then allowed
to grow in 20% or 1% O2 for additional 1 or 2 days. The results were
expressed as relative viability over day 0.
2.10. Data analysis
Results are expressed as mean ± SD. The statistical difference be-
tweenmultiple groupswas analyzedusing oneway ANOVA.Differences
between two groups were analyzed by Student's t test. Experiments
were performed in triplicate and were performed at least three times.
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3.1. SET9 interacts with HIF-1α
To investigate the role of transcriptional co-factors in HIF-1 function,
we initially tested whether histone methyltransferases interact with
HIF-1α. We identiﬁed SET9 as a potential HIF-1α interacting protein.
We co-overexpressed HA-SET9 with FLAG-HIF-1α in HEK293T cells
and performed co-immunoprecipitation (co-IP) assay using anti-FLAG
antibody. HA-SET9 was detected by western blots in the cell lysates
immunoprecipitated with anti-FLAG antibody, suggesting that SET9
interacted with HIF-1α (Fig. 1A). Next, we co-overexpressed HA-HIF-
1α and FLAG-SET9 in HEK293T cells and treated cells with or without
hypoxia (1% O2) before co-IP. We found that HA-HIF-1α was present
in cell lysates immunoprecipitated by anti-FLAG antibody, and the
signal was higher in hypoxia compared to normoxia, in consistent
with higher total HIF-1α levels in hypoxia (Fig. 1B). To conﬁrm these
results, U2OS cellswere transfectedwith SET9 and treatedwith hypoxic
mimetic CoCl2. Endogenous HIF-1α was immunoprecipitated using
anti-HIF-1α antibody. Western blots showed that SET9 was able to
interact with the endogenous HIF-1α (Fig. 1C). We also examinedHA-HIF-1α
FLAG-SET9
IP: FLAG
N         H N    H N    H
IP: IgG WCL
FLAG-HIF-1α
HA-SET9
FLAG IgG
WCLIP
FLAG IgG
HIF-1α
FLAG-SET9
IP: HIF-1α WCL
EV  SET9 EV  SET9
A
B
C
FLAG WCLIP: IgG
HA-HIF-2α
FLAG-SET9
D
HA-HIF-2α
long exposure
Fig. 1. SET9 interactswithHIF-1α. A. Co-immunoprecipitation (Co-IP) of FLAG-HIF-1α and
HA-SET9 using anti-FLAG antibody. HEK293T cells were transfected with FLAG-HIF-1α
and HA-SET9 for 48 h. Whole cell lysates (WCL) were immunoprecipitated with anti-
FLAG antibody or IgG. IP products were probed with anti-FLAG and anti-HA antibodies.
B. Co-IP of FLAG-SET9 and HA-HIF-1α using anti-FLAG antibody. HEK293T cells were
transfected with FLAG-SET9 and HA-HIF-1α for 48 h and exposed to 20% (N) or 1% O2
(H) for 4 h. WCL were subject to IP with anti-FLAG antibody or IgG, and probed with
anti-FLAG or anti-HA antibodies. C. Co-IP of endogenous HIF-1α and FLAG-SET9 using
anti-HIF-1α antibody. U2OS cells were transfected with Empty Vector (EV) or FLAG-
SET9 for 48 h and treated with CoCl2 for 4 h. Cell lysates were subject to IP with anti-
HIF-1α antibody, and then probed with anti-HIF-1α or anti-FLAG antibodies. D. Co-IP of
FLAG-SET9 and HA-HIF-2α using FLAG antibody. HEK293T cells were transfected with
FLAG-SET9 and HA-HIF-2α for 48 h. WCL were subject to IP with anti-FLAG antibody or
IgG, and probed with anti-HA or anti-FLAG antibodies.whether SET9 interacts with HIF-2α, the other major hypoxia inducible
transcription factor. We co-overexpressed FLAG-SET9 and HA-HIF-2α
in HEK293T cells and performed co-IP with anti-FLAG antibody. The
results showed that HIF-2α was not co-immunoprecipitated with
SET9. Longer exposure was unable to detect HA-HIF-2α band in the IP
products either (Fig. 1D), suggesting that SET9 speciﬁcally interacts
with HIF-1α but not HIF-2α.
3.2. SET9 stabilizes HIF-1α protein in hypoxia
To determine whether SET9 affects HIF-1α protein levels, we
overexpressed SET9 in U2OS cells and cultured cells in normoxia or
hypoxia. We found that SET9 overexpression in normoxia had no effect
on theHIF-1α protein level. The overexpressed Flag-HIF-1αwasused as
a positive control for western blot detection (Fig. 2A left). On the other
hand, SET9 overexpression in hypoxia signiﬁcantly increased both the
endogenous (Fig. 2A right) and the overexpressed HIF-1α proteins
(Fig. 2B). In contrast, when we knocked down SET9 in U2OS and
Hep3Bc1 cells using two different siRNA sequences targeting SET9
(Fig. 2C and D), we found that both SET9 siRNA constructs decreased
the endogenous HIF-1α levels in hypoxia, with the ﬁrst construct (s1)
showing higher knockdown efﬁciency of SET9 and correspondingly
more obvious HIF-1α level decrease. Scramble control siRNA (SET9
siRNA-, or C)was used as negative control in all experiments. To further
conﬁrm the results, we knocked down SET9 using the ﬁrst siRNA
construct in additional human cell lines including HEK293T, DU145,
C42B and U87. The results showed that knockdown of SET9 by siRNA
in hypoxia decreased HIF-1α levels (Fig. 2E). This effect appears to be
speciﬁc to HIF-1α because knockdown of SET9 did not decrease HIF-
1β (Fig. 3A) or HIF-2α levels (Fig. 3B). Of note, U2OS cells showed
very weak HIF-2α signal even in hypoxia, which is consistent with a
previous report [36]. Taken together, these data suggest that SET9 pos-
itively regulates HIF-1α in hypoxia.
Next, we determined the mechanism by which SET9 increases
HIF-1α in hypoxia. We found that SET9 siRNA in hypoxia did not af-
fect HIF-1αmRNA transcription (Fig. 3C). In addition, SET9 siRNA did
not affect the phosphorylation of p70S6K or S6 in hypoxia, which is
involved in the translation of HIF-1α protein (Fig. 3D). In contrast,
we found that the proteasome inhibitor MG132 could rescue SET9
siRNA induced HIF-1α protein decrease in hypoxia (Fig. 3E). Further,
we found that SET9 siRNA increased the level of HIF-1α protein
polyubiquitination in hypoxic condition (Fig. 3F). Therefore, these
data suggest that SET9 protects HIF-1α protein from proteasomal
degradation in hypoxia.
To further determine the effect of SET9 onHIF-1α protein stability in
hypoxia, we measured the HIF-1α protein degradation kinetics by a
cycloheximide-based assay as previously described [32]. We found
that SET9 overexpression increased HIF-1α protein stability in hypoxic
condition compared to the EV control. A representative western blot
of HIF-1α protein is shown in Fig. 4A. Densitometry of HIF-1α protein
bands in western blots suggested that HIF-1α protein level decreased
to basal level after 30 min of CHX treatment in EV transfected cells,
while in SET9 overexpressing cells HIF-1α remained at higher level
(p b 0.05, Fig. 4B). These results suggested that SET9 stabilized HIF-1α
protein in hypoxia.
The E3 ubiquitin ligase CHIP was reported to mediate ubiquitin-
proteasomal degradation of HIF-1α protein in hypoxia by binding to
HIF-1α [15]. Thus, we tested the hypothesis that SET9 may stabilize
HIF-1α protein by preventing CHIP-mediated HIF-1α degradation.
HEK293T cells were co-transfected with plasmids encoding FLAG-HIF-
1α plus HA-SET9 and/or CHIP. The protease inhibitor MG132 was
added to overcome the effect of SET9 and CHIP onHIF-1α protein levels.
Whole cell lysates were immunoprecipitated with anti-FLAG antibody
(Fig. 4C). Both HA-SET9 and CHIP were co-immunoprecipitated with
FLAG-HIF-1α. Notably, we found that HA-SET9 reduced the interaction
between HIF-1α and CHIP. Next, we co-overexpressed SET9 and/or
HIF-1α
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-
Fig. 2. SET9 positively regulates HIF-1α in hypoxia. A. SET9 overexpression increased endogenous HIF-1α protein levels in hypoxia. Left. U2OS cells were transfected with HA-SET9 or
FLAG-HIF-1α for 48 h. Right. U2OS cells were transfected with increasing amounts of HA-SET9 plasmid as indicated for 48 h, and exposed to 1% O2 for 4 h. Cell lysates were probed
using anti-HIF-1α or anti-HA antibodies. Fluorescent signals of HIF-1α bands were quantiﬁed by the Odyssey software, adjusted by β-tubulin signals, and normalized to empty vector
transfected cells in 1% O2. The values are shown below the HIF-1α blot. B. SET9 overexpression increased exogenous HIF-1α levels. HEK293T cells were transfected with FLAG-HIF-1α
and HA-SET9 for 48 h and exposed to 1% O2 for 4 h. Cell lysates were probed using anti-FLAG or anti-HA antibodies. C and D. Knockdown of SET9 by different siRNA constructs decreased
HIF-1α levels inU2OS (C) andHep3Bc1 (D) cells. Cells were transfectedwith scramble control siRNA (−) or two constructs of SET9 siRNA (s1 and s2) for 48 h and exposed to 20% or 1%O2
for 4 h. NT, non-transfected. Cell lysates were probed using anti-HIF-1α or anti-SET9 antibodies. E. siRNA knockdown of SET9 decreased HIF-1α levels in multiple cell lines. HEK293T,
DU145, C42B and U87 cells were transfected with scramble control siRNA (−) or SET9 siRNA (+) for 48 h and exposed to 20% or 1% O2 for 4 h. Cell lysates were probed using anti-
HIF-1α or anti-SET9 antibodies. In all the experiments β-tubulin levels were used as loading controls. Results shown are representative of three independent experiments.
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showed that overexpression of SET9 increased HIF-1α level, while
overexpression of CHIP decreased HIF-1α level. Importantly, co-
overexpression of both SET9 and CHIP rescued CHIP mediated HIF-1α
protein decrease (Fig. 4D). These observations are consistent with
the hypothesis that SET9 stabilizes HIF-1α protein by attenuating
CHIP-mediated degradation.
Finally, since SET9 is a methyltransferase, we also investigated
whether the methyltransferase activity could contribute to the regula-
tion HIF-1α stability. The SET9 H297A mutant is defective in methyl-
transferase activity [28]. We co-overexpressed HIF-1α with different
doses of wild type and mutant SET9 in U2OS cells to examine its ability
to stabilize HIF-1α protein. We found that both SET9 wild-type and
methyltransferase defective mutant increased HIF-1α protein levels,
suggesting that the methyltransferase activity is not essential for SET9
to stabilize HIF-1α.3.3. SET9 knockdown decreases HIF-1 transactivation and selectively
attenuates a subset of HIF-1 target gene expression in hypoxia
Nextwe examinedwhether SET9 could regulateHIF-1 transcription-
al activity. We performed reporter gene assays in Hep3Bc1 cells, which
had been stably co-transfected with a ﬁreﬂy luciferase gene under the
control of a HIF-1 responsive hypoxia response element (HRE) and
with a constitutive renilla luciferase gene [31]. HIF-1 transcriptional
activity was determined by the ratio of ﬁreﬂy/renilla and normalized
to scramble control siRNA (siC) transfected cells in normoxia. We
found that HIF-1 transcriptional activity was signiﬁcantly increased at
1% O2 compared to 20% O2 as expected, and SET9 siRNA signiﬁcantly
reduced the activity in 1% O2 compared to scramble control siRNA
(p b 0.05, Fig. 5A). To further conﬁrm the results, HEK293T cells were
co-transfectedwithHRE-drivenﬁreﬂy and constitutive renilla luciferase
plasmids. The reporter activities were measured in normoxia and
HIF-1β
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F
Fig. 3. SET9 regulates HIF-1α protein degradation in hypoxia. A. SET9 siRNA did not affect HIF-1β levels in U2OS cells. B. SET9 siRNA did not affect HIF-2α levels in U87 cells. C. SET9 siRNA
did not affect HIF-1αmRNA levels in U2OS cells. D. SET9 siRNA did not affect p70S6K or S6 phosphorylation in HIF-1α protein translation machinery. E. MG132 rescued SET9 siRNA
induced HIF-1α protein level decrease. U2OS cells were treated with MG132 (20 μM) for 4 h. F. SET9 siRNA increased HIF-1α ubiquitination. MG132 (20 μM) and CoCl2 (150 μM) were
incubated for 4 h. Cell lysates were immunoprecipitated with anti-HIF-1α antibody or IgG. In all the experiments cells were transfected with scramble control (−) or SET9 siRNA (+)
for 48 h and exposed to 20% or 1% O2 for 4 h (24 h for mRNA levels). Cell lysates were probed using indicated antibodies. β-Tubulin levels were used as loading controls. Results
shown are representative of three independent experiments.
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while SET9 siRNA signiﬁcantly attenuated the increase (p b 0.001,
Fig. 5B), suggesting an inhibition of HIF-1.
Next, to determine whether SET9 regulates HIF-1 target gene
expression, U2OS cells were transfected with siC or siSET9 siRNAs and
exposed to 20%O2 or 1%O2 for 24 h. Real-timeqRT-PCR analysis showed
that hypoxia induced HIF-1 target gene expression as expected, while
SET9 knockdown decreased the expression of a subset of HIF-1 target
genes, including HK2, LDHA and PDK1, which are key regulators of
the glycolysis pathway [37]. Interestingly several HIF-1α target genesremain unaffected by siSET9, such as VEGFa, JMJD1A and JMJD2C
(Fig. 5C). Next, we overexpressed SET9 and examined HIF-1α target
gene levels. The results showed that SET9 overexpression increased
LDHA, HK2 and PDK1 mRNA in hypoxia (Fig. 5D). The increase was
not statistically different, which could be due to the already high endog-
enous SET9 level in U2OS cells.
To conﬁrm the differential HIF-1 target gene regulation by SET9, we
examined HIF-1 target gene levels in Hep3Bc1 shC and shHIF-1α cells
after SET9 knockdown (Fig. 6). Similar to U2OS cells, SET9 siRNA
decreased hypoxia induced glycolytic gene expression (HK2, LDHA
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Fig. 4. SET9 protects HIF-1α from proteasome degradation in hypoxia. A. SET9 increased HIF-1α protein stability. U2OS cells were transfected with empty vector (EV) or SET9 expression
plasmid, then treated with CoCl2 (150 μM, 4 h) and the protein synthesis inhibitor cycloheximide (CHX) for indicated time points. B. Fluorescent signals of HIF-1α bands from three in-
dependent experimentswere quantiﬁed by theOdyssey software, adjusted byβ-tubulin signals, and normalized to signals in normal condition. *p b 0.05. C. SET9 inhibited the recruitment
of E3 ligase CHIP to HIF-1α. HEK293T cells were transfected with FLAG-HIF-1α, HA-SET9 and CHIP plasmids as indicated for 48 h, and exposed to 1% O2 andMG132 (20 μM) for 4 h. Cell
lysates were immunoprecipitated with anti-FLAG antibody or IgG. D. SET9 rescued CHIP mediated HIF-1α protein degradation. HEK293T cells were transfected with FLAG-HIF-1α, HA-
SET9 and CHIP plasmids as indicated for 48 h, and exposed to 1% O2 for 4 h. E. Effect of SET9 methyltransferase-deﬁcient mutant H297A on HIF-1α protein levels. U2OS cells were
transfected with FLAG-HIF-1α and 0.5 or 1 μg FLAG tagged wild type SET9 (FLAG-SET9 wt) or SET9 H297A mutant (FLAG-SET9 mt) for 48 h. Cells were exposed to 1% O2 for 4 h prior
to harvest. β-Tubulin was used as loading controls in all experiments. Results shown are representative of three independent experiments.
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shC cells. This selective inhibition of HIF-1 target genes by SET9 siRNA
was in sharp contrast to the uniform inhibition by HIF-1α-shRNA
(shHIF-1α, Fig. 6). Also, SET9 siRNA could not further decrease the gly-
colytic HIF-1 target genes under the condition of HIF-1α shRNA (Fig. 6).
These results suggested that the selective down-regulation of glycolytic
genes by SET9 siRNA was HIF-1α dependent.
3.4. SET9 regulates HIF-1α enrichment at a subset of HIF-1 target gene
promoters
Next, we sought to investigate themechanism by which SET9 selec-
tively regulates HIF-1 target gene expressions. Since SET9 was reported
to be a histone methyltransferase and could activate gene expressionthrough epigenetic mechanisms, we hypothesized that SET9 binds
to chromatins of HREs within HIF-1α target genes that are affected
by SET9 siRNA in Figs. 5 and 6. To test this hypothesis, we preformed
chromatin co-immunoprecipitation (ChIP) assays in U2OS cells using
anti-SET9 antibody and PCR primers amplifying HREs regions, which
are proven HIF-1α binding sites [27] within the HIF-1 target genes in
Figs. 5 and 6. The results showed that, in consistency with gene expres-
sion data, SET9 was highly enriched on HREs of HK2, LDHA and PDK1,
but not on HREs of VEGFa, JMJD1A and JMJD2C (Fig. 7A).
Since mono-methylation of histone H3K4 by SET9 was related to
gene activation, we next examined whether SET9 could affect the levels
of mono-methylated H3K4 (H3K4me) in chromatins of HREs. ChIP
assay was performed in U2OS cells using anti-H3K4me antibody, and
primers amplifying HRE regions. To exclude the interference of internal
A B
D
Hep3Bc1 HEK293T
C
Fig. 5. SET9 knockdown decreases HIF-1 transactivation and a subset of HIF-1 target gene expressions. SET9 knockdown decreased hypoxia induced HIF-1 transcriptional activity in
A. Hep3Bc1 and B. HEK293T cells. Relative HRE activity was calculated as fold change to controls (siC cells in 20% O2). C. SET9 siRNA decreased HIF-1 regulated glycolytic gene (LDHA,
HK2 and PDK1) transcription but not VEGFa, JMJD1A or JMJD2C transcription in U2OS cells. HIF-1 target gene mRNA levels were expressed as fold change over control (siC cells in 20%
O2). D. Effect of SET9 overexpression on glycolytic gene transcription in U2OS cells. *p b 0.05, **p b 0.01, ***p b 0.001, ND, not signiﬁcantly down-regulated.
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lated the enrichment as fold over empty vector (EV) control. In the two
groups of genes distinguished by high or low SET9 enrichment (Fig. 7A),
we selected one gene from each group for testing. The results showed
that SET9 overexpression increased H3K4me levels in HRE of LDHA,
which has high SET9 enrichment, but not that of JMJD2C (Fig. 7B),
which has low SET9 enrichment. These results suggest that SET9 selec-
tively binds to HREs of glycolytic gene and enhanced the mono-
methylation levels of H3K4 within these sites.
Nextwe examinedwhether SET9 could affect HIF-1α enrichment on
chromatins of HRE. We performed ChIP assays using anti-HIF-1α anti-
body in U2OS cells stably transfected by shRNA against non-targeting
control (shC) or SET9 (shSET9). The results showed that hypoxia
induced enrichment of HIF-1α on HREs of all HIF-1α target genes as
reported previously, while SET9 knockdown speciﬁcally decreasedHIF-1α levels on HREs of HK2, LDHA and PDK1 but not VEGFa, JMJD1A
and JMJD2C (Fig. 7C). Taken together, the above results suggest
that SET9 speciﬁcally enriches at HREs of selective HIF-1 target genes,
thereby promoting transcriptionally active chromatin formation and
increasing HIF-1α stability at these sites, together which lead to the
upregulation of these genes in hypoxia.
3.5. SET9 regulates HIF-1 dependent glycolyticmetabolism and cell viability
Because HK2, LDHA, and PDK1 are key components of the glycolysis
pathway, we next determined whether SET9 could affect HIF-1 depen-
dent hypoxic glycolysis in cancer cells by measuring extracellular lac-
tate levels. Consistent with the expression of glycolytic genes, hypoxia
induced signiﬁcant increase of lactate levels in both Hep3Bc1 (Fig. 8A)
and U2OS (Fig. 8B) cells, while SET9 siRNA signiﬁcantly decreased
Fig. 6. SET9 knockdown decreases glycolytic gene expressions in Hep3Bc1 cells. Hep3Bc1 shC and shHIF-1α cells were transfectedwith siC or siSET9 for 48 h and exposed to 20% or 1% O2
for 24 h prior to harvest. HIF-1α target gene mRNA levels were determined by RT-PCR. *p b 0.05, **p b 0.01, ND, not signiﬁcantly down-regulated.
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that SET9 regulates lactate production through HIF-1α, we measured
lactate levels in HIF-1α stable knockdown cells (Fig. 8C). The resultsFig. 7. SET9 regulates HIF-1α enrichment on chromatins of glycolytic geneHREs. A. SET9 speciﬁc
for 24 h and chromatin immunoprecipitation (ChIP)was performed using anti-SET9 antibody a
methylation levels in LDHA HRE region. U2OS cells were transfectedwith empty vector (EV) or
and primers for LDHA and JMJD2C as in A. C. Knockdown of SET9 speciﬁcally reduced HIF-1α bin
using anti-HIF-1α antibody and the same primers as in A. *p b 0.05, **p b 0.01, ND, not signiﬁcshowed that hypoxia increased lactate levels in U2OS shC cells but failed
to induce lactate production in HIF-1α stable knockdown cells (shHIF-
1α). SET9 siRNA decreased lactate levels in U2OS shC cells, but couldally enriched onHREswithin glycolytic gene promoters. U2OS cells were exposed to 1%O2
nd primers speciﬁc to theHREswithin HIF-1α target genes. B. SET9 enhancedH3K4mono-
SET9 and exposed to 1% O2 for 24 h. ChIP analysis was performed using H3K4me antibody
ding to HREs in glycolytic genes but not in VEGFa, JMJD1A or JMJD2C. ChIPwas performed
antly down-regulated.
Fig. 8. SET9 knockdown decreases lactate production and cell viability in hypoxia. SET9 siRNA reduced hypoxia induced lactate production in A. Hep3Bc1 and B. U2OS cells. Lactate levels
were expressed as fold change to controls (siC cells in 20% O2). C. SET9 siRNA failed to further reduce lactate levels in HIF-1α knockdown U2OS cells. Lactate levels were expressed as fold
change to controls (shC-siC cells in 20%O2). D. SET9 siRNA inhibited cell viability under hypoxia. Relative cell viabilitywas expressed as fold change to day 0 inhypoxia. *pb 0.05, **p b 0.01,
***p b 0.001.
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ing that SET9 regulates extracellular lactate production and hypoxic
glycolysis through HIF-1α.
Transition to glycolytic phenotype plays an important role in meta-
bolic adaptation to hypoxic stress. Given that HIF-1α is a key regulator
for cancer cell adaptation and survival in hypoxia, we next examined
whether SET9 knockdown could affect cell viability in hypoxia. U2OS
cells with control shRNA (shC) or SET9 shRNA (shSET9) stable knock-
down were cultured in normal oxygen for 24 h and then exposed to
20% or 1% O2 for additional 1 or 2 days (Fig. 8D). The results showed
that cell viability was signiﬁcantly decrease in 1% O2 compared with
20% O2. Stable knockdown of SET9 did not affect cell viability in 20%
O2, but signiﬁcantly decreased cell viability in 1% O2 compared to con-
trol shRNA knockdown after 1 or 2 days in hypoxia.
4. Discussion
In the present study, we demonstrate that SET9 promotes HIF-1α
protein stability in hypoxia, and selectively regulates a subset of HIF-1
target gene expression which mediates hypoxic glycolysis.
The transcription factor HIF-1 plays an essential role in cellular adap-
tation to hypoxic stress and is widely considered as a therapeutic target
to treat cancer. Our results showed that SET9 was able to interact with
HIF-1α and regulate HIF-1α protein stability as well as downstream
functions. In hypoxic conditions, HIF-1α is stabilized due to the lack of
oxygen-dependent PHD/VHL-HIF-1α protein degradation pathway.
Despite the increased stability, HIF-1α protein can still be negatively
regulated in hypoxia. For example, HSP70 interacts with HIF-1α and
recruits the E3 ubiquitin ligase CHIP to HIF-1α, therefore leading to
proteasomal degradation of HIF-1α in hypoxia [15]. Our results showed
that SET9 interacts with HIF-1α and stabilizes HIF-1α by inhibiting the
E3 ubiquitin ligase CHIP recruitment, suggesting that SET9 competes
with HSP70 or CHIP for binding to HIF-1α, therefore protects HIF-1α
from exposing to the proteasomal degradation system. The detailedmechanisms are under investigation in our ongoing study. As a methyl-
transferase, it is also possible that SET9 directly methylates HIF-1α and
makes it structurally unfavorable for binding of the components in pro-
tein degradation machinery. In addition, SET9 may methylate HSP70 or
CHIP and interfere with HIF-1α protein stability. However, our data
showed that loss of methyltransferase activity does not abrogate the
ability of SET9 to stabilize HIF-1α. More detailed mechanistic investiga-
tions are needed to unveil how SET9 stabilizes HIF-1α in hypoxia.
In normal oxygen conditions, only low level of HIF-1αwas observed
due to oxygen-dependent degradation machinery [38]. Our results
showed that SET9 knockdown could not affect HIF-1α levels in
normoxia, and overexpression of SET9 failed to increase HIF-1α protein
in normoxia. These ﬁndings suggest that oxygen-dependent mecha-
nism overrides the role SET9 in HIF-1α protein stability in normal
condition, and that SET9 regulates HIF-1α stability in hypoxia, which
represents the physiological condition in which HIF-1α plays a func-
tional role [10].
In consistency with the protein level down-regulation, SET9 knock-
downdecreased hypoxia inducedHIF-1 target gene expressions, includ-
ing HK2, LDHA and PDK1 which are core components of the glycolysis
pathway. Interestingly, knockdown of SET9 does not affect several
other HIF-1 target gene expressions such as VEGFa, JMJD1A and
JMJD2C. This differential regulation of HIF-1 target genes was observed
in two cell lines in this study and also in other studies [39–41], however
the mechanism was unclear. Since SET9 mainly functions as a histone
methyltransferase and activates gene expression through transcription-
ally active chromatin structure formation, we speculated that SET9
regulates HIF-1 transactivation on the chromatin level.
Indeed, further study using chromatin immunoprecipitation showed
that in consistencywith gene expression data, SET9 speciﬁcally binds to
the chromatin of HRE sites within glycolytic gene promoters, which are
known HIF-1α binding sites. In addition, SET9 was able to increase
H3K4me levels in glycolytic gene HREs. More importantly, knockdown
of SET9 speciﬁcally decreased HIF-1α binding level at these glycolytic
890 Q. Liu et al. / Biochimica et Biophysica Acta 1853 (2015) 881–891gene HRE sites (HK2, LDHA and PDK1), whereas SET9 knockdown does
not affect HIF-1α levels on HRE sites without SET9 binding (VEGFa,
JMJD1A and JMJD2C). These ﬁndings suggest that the regulation of
HIF-1α by SET9 is likely to occur on chromatin level, and that SET9
serves as a cofactor to speciﬁcally regulate HIF-1α protein stability at
promoter HREs, therefore promoting the glycolytic adaptation of cancer
cells when oxygen is limited. Expansion of the current study to a larger
gene proﬁle would help to further address the mechanism. Additional
cofactors including gene transcription activation and suppression
complexes, such as p300/CBP [21,42] are likely to be involved in
directing SET9 to chromatins of speciﬁc glycolytic gene HREs. In addi-
tion to our ﬁndings, the histone demethylase JMJD2C was reported to
be a coactivator for HIF-1α in breast cancer progression [24]. SET9
was reported to methylate estrogen receptor (ER) and facilitate the
recruitment of ER to its target genes, thus serving as a coactivator for
gene transcription [43]. Taken together, these studies reveal a novel
mechanism that histone modifying enzymes coordinate epigenetic
signals with transcription factors to achieve gene speciﬁc regulation in
cancer cell function.
Targeting HIF-1α represents a promising strategy in treating cancer,
and an increasing number of HIF-1α inhibitors have been developed,
although few of them progressed through preclinical stage [31,44–46].
Due to the large numbers of genes regulated by HIF-1α, it is important
to selectively regulate HIF-1α function to minimize side effects [47].
Our study establishes that the histone methyltransferase SET9 selec-
tively regulates HIF-1mediated glycolytic gene expressions in cancer
cells, thus affecting glycolytic metabolism in cancer cells. Future
xenograft assays are planned to further conﬁrm our ﬁndings. Recently,
several SET9 inhibitors with high potency and selectivity have been
developed in high throughput screening assays [48]. However, the
role of SET9 in disease pathwayswas poorly understood. Our study pro-
vides foundationalmechanisms for utilization of SET9 inhibitors to treat
cancer and will greatly facilitate the development of SET9 inhibitors for
disease treatment.Acknowledgements
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